Literature DB >> 25024169

Discovery and mapping of an intracellular antagonist binding site at the chemokine receptor CCR2.

Annelien J M Zweemer1, Julia Bunnik1, Margo Veenhuizen1, Fabiana Miraglia1, Eelke B Lenselink1, Maris Vilums1, Henk de Vries1, Arthur Gibert1, Stefanie Thiele1, Mette M Rosenkilde1, Adriaan P IJzerman1, Laura H Heitman2.   

Abstract

The chemokine receptor CCR2 is a G protein-coupled receptor that is involved in many diseases characterized by chronic inflammation, and therefore a large variety of CCR2 small molecule antagonists has been developed. On the basis of their chemical structures these antagonists can roughly be divided into two groups with most likely two topographically distinct binding sites. The aim of the current study was to identify the binding site of one such group of ligands, exemplified by three allosteric antagonists, CCR2-RA-[R], JNJ-27141491, and SD-24. We first used a chimeric CCR2/CCR5 receptor approach to obtain insight into the binding site of the allosteric antagonists and additionally introduced eight single point mutations in CCR2 to further characterize the putative binding pocket. All constructs were studied in radioligand binding and/or functional IP turnover assays, providing evidence for an intracellular binding site for CCR2-RA-[R], JNJ-27141491, and SD-24. For CCR2-RA-[R] the most important residues for binding were found to be the highly conserved tyrosine Y(7.53) and phenylalanine F(8.50) of the NPxxYx(5,6)F motif, as well as V(6.36) at the bottom of TM-VI and K(8.49) in helix-VIII. These findings demonstrate for the first time the presence of an allosteric intracellular binding site for CCR2 antagonists. This contributes to an increased understanding of the interactions of diverse ligands at CCR2 and may allow for a more rational design of future allosteric antagonists.
Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25024169     DOI: 10.1124/mol.114.093328

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  13 in total

1.  Allosteric Activation of a G Protein-coupled Receptor with Cell-penetrating Receptor Mimetics.

Authors:  Ping Zhang; Andrew J Leger; James D Baleja; Rajashree Rana; Tiffany Corlin; Nga Nguyen; Georgios Koukos; Andrew Bohm; Lidija Covic; Athan Kuliopulos
Journal:  J Biol Chem       Date:  2015-05-01       Impact factor: 5.157

2.  The Angiotensin Receptor Blocker Losartan Suppresses Growth of Pulmonary Metastases via AT1R-Independent Inhibition of CCR2 Signaling and Monocyte Recruitment.

Authors:  Daniel P Regan; Jonathan W Coy; Kirti Kandhwal Chahal; Lyndah Chow; Jade N Kurihara; Amanda M Guth; Irina Kufareva; Steven W Dow
Journal:  J Immunol       Date:  2019-04-10       Impact factor: 5.422

Review 3.  What Do Structures Tell Us About Chemokine Receptor Function and Antagonism?

Authors:  Irina Kufareva; Martin Gustavsson; Yi Zheng; Bryan S Stephens; Tracy M Handel
Journal:  Annu Rev Biophys       Date:  2017-05-22       Impact factor: 12.981

Review 4.  Structural Analysis of Chemokine Receptor-Ligand Interactions.

Authors:  Marta Arimont; Shan-Liang Sun; Rob Leurs; Martine Smit; Iwan J P de Esch; Chris de Graaf
Journal:  J Med Chem       Date:  2017-03-10       Impact factor: 7.446

5.  Lipopeptide Pepducins as Therapeutic Agents.

Authors:  Emily Michael; Lidija Covic; Athan Kuliopulos
Journal:  Methods Mol Biol       Date:  2022

6.  Hydroxyl Groups on Annular Ring-B Dictate the Affinities of Flavonol-CCL2 Chemokine Binding Interactions.

Authors:  Nidhi Joshi; Deepak Kumar Tripathi; Nupur Nagar; Krishna Mohan Poluri
Journal:  ACS Omega       Date:  2021-04-06

7.  Design and Characterization of an Intracellular Covalent Ligand for CC Chemokine Receptor 2.

Authors:  Natalia V Ortiz Zacarías; Kirti K Chahal; Tereza Šimková; Cas van der Horst; Yi Zheng; Asuka Inoue; Emy Theunissen; Lloyd Mallee; Daan van der Es; Julien Louvel; Adriaan P IJzerman; Tracy M Handel; Irina Kufareva; Laura H Heitman
Journal:  J Med Chem       Date:  2021-02-18       Impact factor: 7.446

8.  Functional inhibition of chemokine receptor CCR2 by dicer-substrate-siRNA prevents pain development.

Authors:  Valérie Bégin-Lavallée; Élora Midavaine; Marc-André Dansereau; Pascal Tétreault; Jean-Michel Longpré; Ashley M Jacobi; Scott D Rose; Mark A Behlke; Nicolas Beaudet; Philippe Sarret
Journal:  Mol Pain       Date:  2016-06-15       Impact factor: 3.395

9.  Structure of CC chemokine receptor 2 with orthosteric and allosteric antagonists.

Authors:  Yi Zheng; Ling Qin; Natalia V Ortiz Zacarías; Henk de Vries; Gye Won Han; Martin Gustavsson; Marta Dabros; Chunxia Zhao; Robert J Cherney; Percy Carter; Dean Stamos; Ruben Abagyan; Vadim Cherezov; Raymond C Stevens; Adriaan P IJzerman; Laura H Heitman; Andrew Tebben; Irina Kufareva; Tracy M Handel
Journal:  Nature       Date:  2016-12-07       Impact factor: 49.962

10.  Pyrrolone Derivatives as Intracellular Allosteric Modulators for Chemokine Receptors: Selective and Dual-Targeting Inhibitors of CC Chemokine Receptors 1 and 2.

Authors:  Natalia V Ortiz Zacarías; Jacobus P D van Veldhoven; Laura Portner; Eric van Spronsen; Salviana Ullo; Margo Veenhuizen; Wijnand J C van der Velden; Annelien J M Zweemer; Roy M Kreekel; Kenny Oenema; Eelke B Lenselink; Laura H Heitman; Adriaan P IJzerman
Journal:  J Med Chem       Date:  2018-10-11       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.